Malpractice exposure for clinicians involved in psychedelic services

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

For licensed healthcare professionals who want to understand the malpractice theories available against them when they are involved with psychedelic services — as dual-licensed facilitators, referring clinicians, integration providers, or practice advisors — and what steps reduce that exposure.

The short answer

A clinician’s malpractice exposure in the psychedelic space depends heavily on the nature of their involvement. A clinician who discusses psilocybin services with a patient under HB 2387’s discussion protection is in a different risk category from one who provides dual-licensed facilitation, who conducts pre-session medication management, or who offers post-session integration therapy. Across all of these activities, the challenge is the same: no formal clinical standard of care for psychedelic-assisted services has been established by any professional association as of early 2026. That absence does not eliminate malpractice exposure — courts and boards will look to other sources to define what a reasonable clinician would have done — but it does mean the standard is contested and fact-intensive. Understanding what those sources are, and structuring practice accordingly, is the most practical risk-reduction available.

The malpractice framework

Medical malpractice in Oregon requires: a duty of care, breach of that duty, causation, and damages. A clinician who has a professional relationship with a patient related to psychedelic services owes a duty of care that is enforceable in civil court. The question in any claim is what the standard of care required — and whether the clinician’s conduct departed from it.

In the psychedelic context, no professional association has published binding clinical practice guidelines for psilocybin-assisted therapy or for clinical support surrounding Oregon’s licensed program. What courts and expert witnesses will look to instead includes: the OPS administrative rules (OAR 333-333) as a regulatory floor for dual-licensed facilitators; published clinical trial protocols from COMPASS Pathways, Johns Hopkins, and NYU as evidence of what careful practitioners do; consensus guidance from organizations including the American Society of Ketamine Physicians, Psychotherapists and Practitioners; emerging training standards from psychedelic therapy training programs; and the clinician’s own representations about their expertise and services.

A clinician who holds themselves out as a specialist in psychedelic-assisted therapy will be held to the standard of that specialty. A clinician who discusses psilocybin as one option among many without claiming specialized expertise occupies a different evidentiary position.

The referring or recommending clinician

A clinician who refers or recommends Oregon’s psilocybin program to a patient takes on professional responsibility for that clinical conversation. HB 2387 protects the clinician from board discipline for the discussion — it does not immunize the clinician from a malpractice claim if the recommendation was negligent.

The most concrete risk is in medication review. A prescribing clinician who recommends psilocybin services without reviewing the patient’s medication list — particularly for lithium, MAOIs, and serotonergic medications that may substantially affect the experience or create risk — has potentially departed from what a reasonably careful clinician would do. Lithium is the most direct example: it is an absolute exclusion from Oregon’s program, and a prescribing clinician whose patient is on lithium and fails to identify and address that contraindication before the patient accesses services has a direct factual connection between the omission and any resulting harm.

The standard for the clinical discussion is not “say nothing about psilocybin.” It is “discuss it the way a reasonable, careful clinician would, given what is known about the patient and the evidence base.”

The dual-licensed facilitator

A dual-licensed clinician operating under HB 2387 faces potential liability under two frameworks simultaneously: OPS discipline for violations of OAR 333-333, and professional malpractice for departures from clinical standards during preparation and integration sessions.

The administration session is the clearest boundary and the clearest malpractice risk. A dual-licensed facilitator who provides clinical services during an administration session — interpreting the client’s experience, making therapeutic suggestions, conducting clinical assessment while the client is under psilocybin’s effects — has violated both OPS rules and, in all likelihood, the standard of care for their clinical profession. The altered state context makes this category of harm particularly serious: a client who receives directive clinical input during a psilocybin experience is in a state of reduced capacity to evaluate or resist that input.

For preparation and integration sessions, the dual-licensed facilitator faces an additional layer of clinical duty beyond the OPS procedural requirements. OPS rules set the floor. Clinical professional standards set a higher requirement for the quality and competence of the clinical work within those procedures. A therapist-facilitator who conducts a preparation session meeting all OPS procedural requirements but misses an obvious clinical contraindication that a reasonable therapist would have caught may satisfy OPS rules while departing from clinical standards.

The integration provider

A clinician who provides post-session integration therapy without holding a facilitator license occupies a distinct position. They are providing clinical services in their professional capacity — not facilitation — and their standard of care is the standard of their clinical profession, not OPS rules. The malpractice risk in this context arises if the clinician makes clinical judgments about the patient’s experience that depart from what a reasonably careful clinician in their field would do.

Integration therapy is not a formally defined clinical modality with an established standard of care. A clinician who holds themselves out as offering specialized integration therapy should be aware that their representations about their expertise will inform the standard against which their conduct is measured.

Malpractice insurance gaps

Standard professional liability policies for healthcare providers frequently exclude coverage for work involving Schedule I substances. A clinician whose psilocybin-related work — whether dual-licensed facilitation, medication management before a session, or integration therapy — falls outside their existing policy coverage is personally exposed for any claim arising from that work.

A clinician who provides any psilocybin-adjacent clinical services should confirm in writing with their malpractice carrier whether that work is covered. If it is not, specialty psychedelic professional liability coverage is available through carriers including TheraCover, Oath Cannabis Insurance, Relm Insurance, and AlphaRoot. Sexual abuse and misconduct coverage — a separate endorsement from standard professional liability — is particularly important for dual-licensed facilitators given the power dynamics of altered states and the elimination of the statute of limitations for post-June 2025 sexual assault claims under HB 3582.

Documentation as risk reduction

Because the standard of care in this space is unsettled, documentation is more important here than in most clinical contexts. A clinician who documents their reasoning — why they discussed psilocybin services with this patient, what medications they reviewed, what the patient understood about the nature of the services, what contraindications were identified or ruled out, and what follow-up clinical care was planned — is in materially better position if a claim arises. Documentation does not substitute for good clinical judgment, but it preserves evidence that good clinical judgment was exercised.

A clinician providing psilocybin-adjacent clinical services should obtain informed consent that addresses the off-label or non-standard nature of those services, the current state of the evidence base, and the specific clinical services the clinician is and is not providing. For a dual-licensed facilitator, the informed consent documentation needs to address which license the clinician is acting under during each session type. A patient who does not understand that their therapist-facilitator is not providing therapy during the administration session has not been fully informed about the nature of what they are receiving.

When public information may be enough

OAR 333-333 sets out the OPS procedural requirements applicable to dual-licensed facilitators. Published Phase 2 and Phase 3 clinical trial protocols and results from COMPASS Pathways, Johns Hopkins, and NYU are available through peer-reviewed literature and investor disclosures. ORS 12.110, 12.115, and 12.118 govern Oregon’s statutes of limitations for personal injury and sexual assault claims.

When you should speak with a lawyer

A clinician who has received a patient complaint, a board inquiry, or a malpractice demand related to psychedelic services should retain legal counsel immediately before responding. A clinician who wants to establish a practice involving dual-licensed facilitation, pre-session medication management, or integration therapy should get legal advice about how to structure informed consent, documentation, and coverage before beginning. A clinician whose existing malpractice carrier has not confirmed coverage for psilocybin-adjacent work should consult with an insurance attorney or broker about whether their coverage is adequate.

You might also want to read

This article is for general informational purposes only and does not constitute legal advice. Laws and regulations governing psilocybin services and professional liability change frequently. For advice specific to your situation, consult a licensed attorney.